Rachelle S Doody

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. pmc Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response
    Marwan Sabbagh
    The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, 10515 W, Santa Fe Drive, Sun City, AZ 85351, USA
    BMC Geriatr 13:56. 2013
  2. ncbi request reprint A phase 3 trial of semagacestat for treatment of Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    N Engl J Med 369:341-50. 2013
  3. ncbi request reprint Reviewing the role of donepezil in the treatment of Alzheimer's disease
    Rachelle S Doody
    Department of Neurology, Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX 07730, USA
    Curr Alzheimer Res 9:773-81. 2012
  4. doi request reprint Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX 07730, USA
    Dement Geriatr Cogn Disord 33:164-73. 2012
  5. doi request reprint Global issues in drug development for Alzheimer's disease
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 7:197-207. 2011
  6. pmc Should EOAD patients be included in clinical trials?
    Kinga Szigeti
    Department of Neurology and Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 7200B Cambridge Street, Suite E5, 101, Houston, TX 77030, USA
    Alzheimers Res Ther 3:4. 2011
  7. doi request reprint Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's d
    Rachelle S Doody
    Effie Marie Cain Chair in Alzheimer s Disease Research, Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 5:133-6. 2009
  8. doi request reprint Identifying amnestic mild cognitive impairment in primary care: a feasibility study
    Rachelle S Doody
    Alzheimers Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Drug Investig 31:483-91. 2011
  9. ncbi request reprint Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
    Rachelle S Doody
    From the Alzheimer s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston R S D Alzheimer s Disease Cooperative Study, Department of Family and Preventive Medicine R G T, R R, X S, and the Department of Neurosciences R G T, R R, P S A, R M, University of California at San Diego, San Diego Indiana Alzheimer Disease Center, Indiana University M F, and Eli Lilly E S, H L S, R M both in Indianapolis the Department of Neuropathology, School of Medicine, and the Department of Neuropathology and Neuroscience, School of Pharmacological Science, University of Tokyo, Tokyo T I Gerontopole, Unité Mixte de Recherche 1027, Centre Hospitalier Universitaire Toulouse, Toulouse, France B V the Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia S J and the Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY K K
    N Engl J Med 370:311-21. 2014
  10. doi request reprint Apolipoprotein E polymorphism and age at onset of Alzheimer's disease in a quadriethnic sample
    Oh Dae Kwon
    Alzheimer s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 30:486-91. 2010

Detail Information

Publications35

  1. pmc Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response
    Marwan Sabbagh
    The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, 10515 W, Santa Fe Drive, Sun City, AZ 85351, USA
    BMC Geriatr 13:56. 2013
    ....
  2. ncbi request reprint A phase 3 trial of semagacestat for treatment of Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    N Engl J Med 369:341-50. 2013
    ..Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease...
  3. ncbi request reprint Reviewing the role of donepezil in the treatment of Alzheimer's disease
    Rachelle S Doody
    Department of Neurology, Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX 07730, USA
    Curr Alzheimer Res 9:773-81. 2012
    ....
  4. doi request reprint Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX 07730, USA
    Dement Geriatr Cogn Disord 33:164-73. 2012
    ..We evaluated the efficacy/safety of donepezil 23 and 10 mg/day in this trial, with respect to concomitant memantine use...
  5. doi request reprint Global issues in drug development for Alzheimer's disease
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 7:197-207. 2011
    ....
  6. pmc Should EOAD patients be included in clinical trials?
    Kinga Szigeti
    Department of Neurology and Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 7200B Cambridge Street, Suite E5, 101, Houston, TX 77030, USA
    Alzheimers Res Ther 3:4. 2011
    ..Finally, we discuss the ethical dilemma of non-abandonment and justice as it pertains to exclusion of the early-onset AD patients from clinical trials...
  7. doi request reprint Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's d
    Rachelle S Doody
    Effie Marie Cain Chair in Alzheimer s Disease Research, Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 5:133-6. 2009
    ....
  8. doi request reprint Identifying amnestic mild cognitive impairment in primary care: a feasibility study
    Rachelle S Doody
    Alzheimers Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Drug Investig 31:483-91. 2011
    ..This study develops an approach to this question, which is necessary for aMCI to become a treatment target...
  9. ncbi request reprint Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
    Rachelle S Doody
    From the Alzheimer s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston R S D Alzheimer s Disease Cooperative Study, Department of Family and Preventive Medicine R G T, R R, X S, and the Department of Neurosciences R G T, R R, P S A, R M, University of California at San Diego, San Diego Indiana Alzheimer Disease Center, Indiana University M F, and Eli Lilly E S, H L S, R M both in Indianapolis the Department of Neuropathology, School of Medicine, and the Department of Neuropathology and Neuroscience, School of Pharmacological Science, University of Tokyo, Tokyo T I Gerontopole, Unité Mixte de Recherche 1027, Centre Hospitalier Universitaire Toulouse, Toulouse, France B V the Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia S J and the Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY K K
    N Engl J Med 370:311-21. 2014
    ..Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain...
  10. doi request reprint Apolipoprotein E polymorphism and age at onset of Alzheimer's disease in a quadriethnic sample
    Oh Dae Kwon
    Alzheimer s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 30:486-91. 2010
    ..We examined the association between the ApoE genotype and age at onset of AD in a quadriethnic group of community-dwelling AD patients...
  11. doi request reprint Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 6550 Fannin, Houston, TX 77030, USA
    Am J Alzheimers Dis Other Demen 25:155-9. 2010
    ..3%). These findings support the safety of donepezil in patients with aMCI. When compared with other studies, however, the data suggest that patients with Alzheimer's tolerate donepezil better than patients with MCI...
  12. doi request reprint Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
    Susan D Rountree
    Department of Neurology, Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 9:338-45. 2013
    ..Long-term observational controlled studies (LTOCs) extend our understanding by providing longitudinal data across multiple stages of Alzheimer's disease (AD)...
  13. ncbi request reprint Refining treatment guidelines in Alzheimer's disease
    Rachelle S Doody
    Baylor College of Medicine, Houston, Texas, USA
    Geriatrics . 2005
    ..This review will conclude with a discussion of how new data on AD treatments will potentially change current treatment parameters...
  14. pmc A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly
    April J Ho
    Laboratory of Neuroimaging, Department of Neurology, University of California School of Medicine, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 107:8404-9. 2010
    ..These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly...
  15. doi request reprint Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
    Lancet 372:207-15. 2008
    ..More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease...
  16. doi request reprint Causes of aggressive behavior in patients with dementia
    Mark E Kunik
    Houston Center for Quality of Care and Utilization Studies, Health Services Research and Development Services, Houston, TX 77030, USA
    J Clin Psychiatry 71:1145-52. 2010
    ..To examine factors predicting development of aggression...
  17. doi request reprint How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Jared F Benge
    Mental Health Care Line, Michael E DeBakey Veteran s Affairs Medical Center, Houston, Tex 77030, USA
    Dement Geriatr Cogn Disord 28:63-9. 2009
    ..The current investigation used item response theory (IRT) analyses to assess the measurement properties of the ADAS-cog across the range of cognitive dysfunction in AD...
  18. ncbi request reprint Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs Aging 25:163-74. 2008
    ..Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD...
  19. pmc Vitamin E use is associated with improved survival in an Alzheimer's disease cohort
    Valory N Pavlik
    Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098, USA
    Dement Geriatr Cogn Disord 28:536-40. 2009
    ..Vitamin E at a dose of 2,000 IU per day has been shown to delay Alzheimer's disease (AD) progression, but recent studies have questioned the safety of this dose level and the overall efficacy of vitamin E in AD treatment...
  20. doi request reprint Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease
    Kinga Szigeti
    Department of Neurology, University at Buffalo SUNY, Buffalo, NY 14203, USA
    J Alzheimers Dis 33:517-23. 2013
    ..The CR1 events are consistent with previous reports. Larger scale studies with deeper genotyping specifically addressing CNV are needed to evaluate the significance of these findings...
  21. pmc Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies
    Alireza Atri
    Department of Neurology, Massachusetts General Hospital, Boston, Mass 02114, USA
    Neurodegener Dis 10:170-4. 2012
    ..Randomized controlled efficacy trials (RCTs), the scientific gold standard, are required for regulatory approval of Alzheimer's disease (AD) interventions, yet provide limited information regarding real-world therapeutic effectiveness...
  22. ncbi request reprint Is functional decline necessary for a diagnosis of Alzheimer's disease?
    Kyung Won Park
    Department of Neurology, Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 24:375-9. 2007
    ..The purpose of this study is to examine baseline differences and annualized cognitive and functional change scores in mild Alzheimer's disease (AD) patients with and without impaired activities of daily living (ADL)...
  23. ncbi request reprint Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease
    Brian D Hoyt
    Department of Psychology, University of Houston, Houston, Tex, USA
    Arch Neurol 62:454-9. 2005
    ..However, findings regarding an association between the APOE epsilon4 allele and the rate of decline in AD have been mixed...
  24. pmc Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease
    David A Wolk
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:10256-61. 2010
    ....
  25. pmc Factors that influence survival in a probable Alzheimer disease cohort
    Susan D Rountree
    Alzheimer s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, 1977 Butler Boulevard, Suite E5, 101, Houston, TX 77030, USA
    Alzheimers Res Ther 4:16. 2012
    ..This longitudinal study examined multiple factors that influence survival in a cohort of Alzheimer patients followed over two decades...
  26. ncbi request reprint Factors affecting deficit awareness in persons with dementia
    A Lynn Snow
    Mental Health Services Research and Development, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 20:133-9. 2005
    ..This study examined factors affecting deficit awareness (DA) and the effects of diagnostic status (dementia and depression), measurement method and DA dimension on these relationships...
  27. ncbi request reprint Current treatments for Alzheimer's disease: cholinesterase inhibitors
    Rachelle S Doody
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Psychiatry 64:11-7. 2003
    ..Therefore, additional therapies for Alzheimer's disease still need to be developed that include more tolerable agents with alternative mechanisms of action and broader efficacy...
  28. doi request reprint Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores
    Steve Balsis
    Department of Psychology, Texas A and M University, College Station, USA
    Alzheimers Dement 8:288-94. 2012
    ..The present article analyzes problems associated with this approach and offers solutions for gaining measurement precision by modeling how the subscales function...
  29. ncbi request reprint Survival among patients with dementia from a large multi-ethnic population
    Stephen C Waring
    Division of Epidemiology, University of Texas School of Public Health, Houston, TX 77030, USA
    Alzheimer Dis Assoc Disord 19:178-83. 2005
    ..Our findings are consistent with previous studies and provide compelling evidence that survival from onset or diagnosis of dementia depends more on age than any other factor...
  30. ncbi request reprint Dimebon as a potential therapy for Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease Research, Baylor College of Medicine, Houston, Texas, USA
    CNS Spectr 14:14-6; discussion 16-8. 2009
    ....
  31. pmc Voxelwise genome-wide association study (vGWAS)
    Jason L Stein
    Laboratory of Neuro Imaging, Department of Neurology, University of California, Los Angeles School of Medicine, Neuroscience Research Building 225E, 635 Charles Young Drive, Los Angeles, CA 90095 1769, USA
    Neuroimage 53:1160-74. 2010
    ..These genes have high relevance to brain structure. This is the first voxelwise genome wide association study to our knowledge, and offers a novel method to discover genetic influences on brain structure...
  32. pmc Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment
    Valory N Pavlik
    Alzheimer s Disease and Memory Disorders Center, 1977 Butler Blvd, Ste E5, 101, Mail Station BCM650, Houston, TX 77030, USA
    Alzheimers Res Ther 3:30. 2011
    ....
  33. doi request reprint We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 4:S21-5. 2008
    ..Further refinements would come by demonstration of how substantial and how enduring the antidementia benefits are...
  34. ncbi request reprint Effects of blood pressure on neuropsychological functioning in Alzheimer's disease
    Robert N Davis
    Department of Psychology, University of Houston, Houston, TX 77204 5022, USA
    Arch Clin Neuropsychol 18:19-32. 2003
    ..These findings may reflect a tendency for less severely demented patients to exhibit normal age-related changes in blood pressure, whereas abnormal patterns may develop with increased dementia severity...
  35. pmc Predicting progression of Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA
    Alzheimers Res Ther 2:2. 2010
    ..The slowest progression group also survives longer. This baseline measure should be considered in the design of long duration Alzheimer's disease clinical trials...